Insider trades
Stuart Poulton, Chief Officer of Karyopharm Therapeutics KPTI, has filed 0 purchases and 16 sales on the open market. Over the past 12 months that comes to a net sale of $55.1K. The latest trade was on 05/14.
Stuart Poulton
EVP, Chief Development Officer
- Company
- Karyopharm Therapeutics KPTI
- First filing
- 23/02/17
- Trades
- 27 trades
- Buys / sales
- 0 / 16
- 12-month net buying
- −$55.1K
- Last trade
- 05/14
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
| Open-market sale | 05/14 | 05/15 | 403 sh | $9.50 | $3,828.5 | −0.4% | |
| Open-market sale | 03/02 | 03/03 | 5,101 sh | $9.41 | $48,000.41 | −5.1% | |
| Open-market sale | 02/17 | 02/19 | 378 sh | $8.63 | $3,262.14 | −0.4% | |
| Open-market sale | 25/09/15 | 25/09/16 | 401 sh | $6.43 | $2,578.43 | −1.4% | |
| Open-market sale | 25/07/29 | 25/07/30 | 191 sh | $4.37 | $834.67 | −0.7% | |
| Open-market sale | 25/03/04 | 25/03/06 | 3,548 sh | $6.29 | $22,316.92 | −11.5% | |
| Open-market sale | 25/02/18 | 25/02/19 | 5,914 sh | $0.63 | $3,725.82 | −1.8% | |
| Open-market sale | 24/07/30 | 24/07/31 | 2,883 sh | $1.06 | $3,055.98 | −0.9% | |
KPTI | Open-market sale | 24/02/29–24/03/01 | 24/03/04 | 22,466 sh2 trades | $1.18avg. | $26,469.87 | −6.4% |
KPTI | Open-market sale | 24/02/15 | 24/02/20 | 5,847 sh2 trades | $1.33avg. | $7,783.44 | −3.4% |
| Open-market sale10b5-1 plan | 23/07/28 | 23/08/01 | 2,845 sh | $1.70 | $4,836.5 | −1.8% | |
KPTI | Open-market sale | 23/02/15 | 23/02/17 | 5,869 sh3 trades | $3.19avg. | $18,716.55 | −8.4% |